Navigation Links
Experts recommend blood, urine testing to diagnose rare adrenal tumors
Date:6/3/2014

Washington, DCThe Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of two types of rare adrenal tumors pheochromocytomas and paragangliomas that can raise the risk of cardiovascular disease and even death if left untreated.

The CPG, entitled "Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline," appeared in the June 2014 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of the Endocrine Society.

Pheochromocytomas are rare, usually noncancerous tumors that form inside the adrenal glands, while paragangliomas are similar tumors that develop outside the glands. The tumors cause the body to produce excess amounts of the hormones epinephrine commonly known as adrenaline and norepinephrine, which is involved in regulating blood pressure. Symptoms of these tumors include high blood pressure, episodic severe headaches, excess sweating, racing heart, feelings of anxiety and trembling.

Experts estimate between 0.1 and 1 percent of patients treated for high blood pressure have pheochromocytomas, according to the National Institutes of Health's National Cancer Institute.

"Correctly diagnosing pheochromocytomas and paragangliomas is extremely important," said Jacques W.M. Lenders, MD, PhD, FRCP, of Radboud University in Nijmegen, the Netherlands, and chair of the task force that authored the guideline. "In addition to the strain these tumors put on the cardiovascular system, between 10 and 17 percent of the tumors can become malignant. Researchers have discovered that at least a third of people with these conditions have a disease-causing genetic mutation, so early detection can benefit family members who may be at risk."

In the CPG, the Endocrine Society recommends that initial testing for pheochromocytomas and paragangliomas include blood or urine tests for metanephrines the products left behind when the body metabolizes epinephrine and norepinephrine. Research has shown blood and urine testing for metanephrines are more effective at identifying patients who have pheochromocytomas or paragangliomas than other testing techniques.

Other recommendations from the CPG include:

  • People who are diagnosed with pheochromocytomas or paragangliomas should be involved in a shared decision-making process with their physicians to evaluate the need for genetic testing;

  • A diagnostic algorithm that takes into account risk factors such as age at tumor presentation and family history should be used to establish which patients would benefit most from genetic testing and which specific gene mutations to test for;

  • People with paragangliomas and those diagnosed with metastatic tumors should be tested for specific gene mutations associated with those conditions;

  • Computed tomography can be used as the first choice imaging technology for determining the location of pheochromocytomas or paragangliomas for surgical treatment;

  • MRI imaging technology is to be used in specific situations, including for patients who have metastatic tumors, for detecting head and neck paragangliomas and for patients in whom radiation exposure should be limited; and

  • Another imaging technology, 18F-fluorodeoxyglucose-positron emission tomography/computed tomography, can be used in patients with metastatic tumors.

The Hormone Health Network offers resources on pheochromocytomas at http://www.hormone.org/diseases-and-conditions/heart-health-and-metabolism/hypertension#Pheochromocytoma.

Other members of the Endocrine Society task force that developed this CPG include: Quan-Yang Duh of the VA Medical Center and University of California, San Francisco; Graeme Eisenhofer of the University Hospital Dresden in Dresden, Germany; Anne-Paule Gimenez-Roqueplo of Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou and Université Paris Descartes in Paris, France; Stefan K.G. Grebe, Mohammad Hassan Murad and William F. Young, Jr. of the Mayo Clinic in Rochester, MN; Mitsuhide Naruse of National Hospital Organisation Kyoto Medical Center in Kyoto, Japan; and Karel Pacak of the Eunice Kennedy Shriver National Institute of Child Health & Human Development in Bethesda, MD.

The Society established the CPG Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis and treatment of endocrine-related conditions. Each CPG is created by a task force of topic-related experts in the field. Task forces rely on scientific reviews of the literature in the development of CPG recommendations. The Endocrine Society does not solicit or accept corporate support for its CPGs. All CPGs are supported entirely by Society funds.

The CPG was co-sponsored by the American Association for Clinical Chemistry and the European Society of Endocrinology.


'/>"/>

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
202-971-3655
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Experts Offer Advice After Yankee Pitchers Trampoline Injury
2. NYU Langone experts present research, clinical advances at neurosurgeons meeting
3. Red Tide Likely in New England This Season, Experts Warn
4. No Proof That Gum Disease Causes Heart Disease, Experts Say
5. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
6. Glaucoma Need Not Steal Sight, Experts Say
7. Healthy Behaviors Extend Life After Cancer, Experts Say
8. Routine Kidney Disease Screening Not Worthwhile, Experts Say
9. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
10. Aim Skin Cancer Warnings at the Young, Too, Experts Say
11. Experts call for clinical trials to test non-skeletal benefits of vitamin D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... today announced the release of two biometric time and attendance tracking products: the ... 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to enable ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... work, the Self-Funding Success website has recently developed and published an informational resource ... ” was created based on common inquiries the site’s team of third party ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... desire to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) ... what dentists should be aware of when utilizing dental laboratories and technicians that ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to earn placements ... channels. , While many results are clear, much of PR is hard to quantify. ... it comes to measurement, firms should always take an all-inclusive approach that takes both ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Silicon Valley Hair ... to announce a new blog post about women’s hair loss. Although hair transplant procedures ... loss as they age. Menopause or genetics can be two reasons a woman may ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BETHESDA, Md. , March 27, 2017  ImMAGE ... that its immunotherapy successfully passed early toxicology and efficacy ... immune system to target a specific protein, MAGE A, ... triple negative breast cancer. After 4 ... was able to show very little toxicity in a ...
(Date:3/27/2017)... SAN MATEO, Calif. , March 27, 2017 ... has been acquired by Ethicon, a division of ... Reflux Management System for the treatment of gastro-esophageal ... on magnetic sphincter augmentation (MSA) technology and the ... European medical centers. Torax Medical was ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
Breaking Medicine Technology: